Founders Who Finish

When the Market Moves Fast, Execution Is the Differentiator

The surgical robotics competitive shift of 2026 is a stress test. The companies that capitalize are the ones whose execution infrastructure was already in place.

April 20, 2026 Founders Who Finish

The competitive dynamics described in today's Field Notes roundup did not develop slowly. Johnson & Johnson submitted its Ottava system for FDA de novo classification in January. CMR Surgical made its formal U.S. introduction in March. Medtronic's Hugo clearance in urology came in December and is already expanding. In under 90 days, the hospital procurement environment shifted from a single-platform question to a four-way evaluation.

If you are building a company in this environment, the question is not whether your device will find a market. The question is whether your team can move fast enough to capitalize on the window before it closes, and whether you have the execution infrastructure in place to do it.

What Separates Founders Who Finish

The companies that get caught by market shifts are almost never caught because they lacked a good device. They get caught because the foundation work was incomplete. The regulatory pathway was directional, not documented. The product definition was inherited from the prototype rather than rebuilt from user needs. The risk file existed, but no one on the team could defend it. When a competitor's clearance changes the hospital's procurement timeline, or an investor's diligence process accelerates, there is no time to go back and build the foundation.

Founders Who Finish is about the execution work that happens before the market window opens. It is the methodology Dave Saunders developed across fifteen years of surgical robotics commercialization, including co-founding Galen Robotics and taking it from a licensed Johns Hopkins technology to FDA De Novo clearance in July 2023.

The book is organized around five execution domains. Not as a checklist. As a disciplined sequence the team builds and owns.

The Five Execution Domains

Step 1

Regulatory Pathway Clarity

Which pathway, why, and what it means for your product roadmap and timeline. Documented in a way your team can defend to investors and the FDA. Not a direction. A decision with a rationale behind it.

Step 2

Product Architecture and Definition

Intended use, user needs, and indications rebuilt from first principles. Not inherited from the prototype. The foundation that everything else in your product program is traceable to.

Step 3

Risk Management Framework

An ISO 14971-aligned risk file that your team understands and can maintain. Not a document produced for a submission. A living artifact of your engineering decisions, organized so the rationale is defensible at any point in development.

Step 4

Requirements and Traceability

Engineering requirements derived from user needs and risks, traceable through controls to tests. The connective tissue of a product program that holds up under both regulatory review and investor diligence.

Step 5

Verification, Validation, and Investor Readiness

A V&V framework that demonstrates safety and performance, aligned with what a serious diligence team needs to see. The technical story that gets a funded company to the next stage.

Companies that work through this sequence have a product program that can absorb external pressure. When a competitor clears, when an investor asks harder questions, when a design review exposes a gap, the foundation is already there. Companies that have not done this work are still building it when the window opens.

Why This Is the Right Time to Read It

The surgical robotics market is entering a period of genuine competition for the first time. Hospital procurement teams that have operated with a single vendor choice for years are now running real evaluations. That changes the requirements for everything in the robotic workflow, including enabling technology, instruments, and software. Companies that are clear about their regulatory pathway, their product definition, and their risk architecture can respond quickly. Companies that are not will spend the next 12 months rebuilding what they should have built two years ago.

Founders Who Finish is the most direct path from where you are to where you need to be. It is the methodology Dave Saunders runs inside every engagement, written in a form you can work through independently or with your team.

About the author

Dave Saunders co-founded Galen Robotics and took the device from a licensed Johns Hopkins technology to FDA De Novo clearance in July 2023. He managed a 35-patent portfolio across the program's development. His tech career spans 35 years, including product work at Bell Labs, global roles at Ascend Communications during the Lucent acquisition, and standards body positions at the IETF and ITU. Since the Galen clearance, he has worked on four additional surgical robotics programs and approximately six other medical device engagements at the same critical stage: working prototype, unclear path forward.

Founders Who Finish

Get the book.

The execution methodology for founders building complex surgical and interventional devices. Written by someone who has done it.

Get the Book at davesaunders.net/book